Literature DB >> 33573712

Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021.

Kamal Abu Jabal1,2,3, Hila Ben-Amram1,2, Karine Beiruti1, Yunis Batheesh1, Christian Sussan1, Salman Zarka1,3, Michael Edelstein1,3.   

Abstract

The BNT162b2 mRNA COVID-19 vaccine showed high efficacy in clinical trials but observational data from populations not included in trials are needed. We describe immunogenicity 21 days post-dose 1 among 514 Israeli healthcare workers by age, ethnicity, sex and prior COVID-19 infection. Immunogenicity was similar by ethnicity and sex but decreased with age. Those with prior infection had antibody titres one magnitude order higher than naïve individuals regardless of the presence of detectable IgG antibodies pre-vaccination.

Entities:  

Keywords:  COVID-19; Israel; immunogenicity; vaccine

Mesh：

Substances：

Year:  2021        PMID： 33573712      PMCID： PMC7879501          DOI： 10.2807/1560-7917.ES.2021.26.6.2100096

Source DB:  PubMed          Journal:  Euro Surveill        ISSN： 1025-496X


  8 in total

1.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

Authors:  Fernando P Polack; Stephen J Thomas; Nicholas Kitchin; Judith Absalon; Alejandra Gurtman; Stephen Lockhart; John L Perez; Gonzalo Pérez Marc; Edson D Moreira; Cristiano Zerbini; Ruth Bailey; Kena A Swanson; Satrajit Roychoudhury; Kenneth Koury; Ping Li; Warren V Kalina; David Cooper; Robert W Frenck; Laura L Hammitt; Özlem Türeci; Haylene Nell; Axel Schaefer; Serhat Ünal; Dina B Tresnan; Susan Mather; Philip R Dormitzer; Uğur Şahin; Kathrin U Jansen; William C Gruber
Journal:  N Engl J Med       Date:  2020-12-10       Impact factor: 91.245

2.  The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers.

Authors:  Sheila F Lumley; Jia Wei; Denise O'Donnell; Nicole E Stoesser; Philippa C Matthews; Alison Howarth; Stephanie B Hatch; Brian D Marsden; Stuart Cox; Tim James; Liam J Peck; Thomas G Ritter; Zoe de Toledo; Richard J Cornall; E Yvonne Jones; David I Stuart; Gavin Screaton; Daniel Ebner; Sarah Hoosdally; Derrick W Crook; Christopher P Conlon; Koen B Pouwels; A Sarah Walker; Tim E A Peto; Timothy M Walker; Katie Jeffery; David W Eyre
Journal:  Clin Infect Dis       Date:  2021-08-02       Impact factor: 9.079

3.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.

Authors:  Lindsey R Baden; Hana M El Sahly; Brandon Essink; Karen Kotloff; Sharon Frey; Rick Novak; David Diemert; Stephen A Spector; Nadine Rouphael; C Buddy Creech; John McGettigan; Shishir Khetan; Nathan Segall; Joel Solis; Adam Brosz; Carlos Fierro; Howard Schwartz; Kathleen Neuzil; Larry Corey; Peter Gilbert; Holly Janes; Dean Follmann; Mary Marovich; John Mascola; Laura Polakowski; Julie Ledgerwood; Barney S Graham; Hamilton Bennett; Rolando Pajon; Conor Knightly; Brett Leav; Weiping Deng; Honghong Zhou; Shu Han; Melanie Ivarsson; Jacqueline Miller; Tal Zaks
Journal:  N Engl J Med       Date:  2020-12-30       Impact factor: 91.245

4.  Natural History of Coronavirus Disease 2019: Risk Factors for Hospitalizations and Deaths Among >26 Million US Medicare Beneficiaries.

Authors:  Hector S Izurieta; David J Graham; Yixin Jiao; Mao Hu; Yun Lu; Yue Wu; Yoganand Chillarige; Michael Wernecke; Mikhail Menis; Douglas Pratt; Jeffrey Kelman; Richard Forshee
Journal:  J Infect Dis       Date:  2021-03-29       Impact factor: 5.226

5.  Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.

Authors:  Mark J Mulligan; Kirsten E Lyke; Nicholas Kitchin; Judith Absalon; Alejandra Gurtman; Stephen Lockhart; Kathleen Neuzil; Vanessa Raabe; Ruth Bailey; Kena A Swanson; Ping Li; Kenneth Koury; Warren Kalina; David Cooper; Camila Fontes-Garfias; Pei-Yong Shi; Özlem Türeci; Kristin R Tompkins; Edward E Walsh; Robert Frenck; Ann R Falsey; Philip R Dormitzer; William C Gruber; Uğur Şahin; Kathrin U Jansen
Journal:  Nature       Date:  2020-08-12       Impact factor: 69.504

6.  Black, Asian and Minority Ethnic groups in England are at increased risk of death from COVID-19: indirect standardisation of NHS mortality data.

Authors:  Robert W Aldridge; Dan Lewer; Srinivasa Vittal Katikireddi; Rohini Mathur; Neha Pathak; Rachel Burns; Ellen B Fragaszy; Anne M Johnson; Delan Devakumar; Ibrahim Abubakar; Andrew Hayward
Journal:  Wellcome Open Res       Date:  2020-06-24

7.  Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

Authors:  Maheshi N Ramasamy; Angela M Minassian; Katie J Ewer; Amy L Flaxman; Pedro M Folegatti; Daniel R Owens; Merryn Voysey; Parvinder K Aley; Brian Angus; Gavin Babbage; Sandra Belij-Rammerstorfer; Lisa Berry; Sagida Bibi; Mustapha Bittaye; Katrina Cathie; Harry Chappell; Sue Charlton; Paola Cicconi; Elizabeth A Clutterbuck; Rachel Colin-Jones; Christina Dold; Katherine R W Emary; Sofiya Fedosyuk; Michelle Fuskova; Diane Gbesemete; Catherine Green; Bassam Hallis; Mimi M Hou; Daniel Jenkin; Carina C D Joe; Elizabeth J Kelly; Simon Kerridge; Alison M Lawrie; Alice Lelliott; May N Lwin; Rebecca Makinson; Natalie G Marchevsky; Yama Mujadidi; Alasdair P S Munro; Mihaela Pacurar; Emma Plested; Jade Rand; Thomas Rawlinson; Sarah Rhead; Hannah Robinson; Adam J Ritchie; Amy L Ross-Russell; Stephen Saich; Nisha Singh; Catherine C Smith; Matthew D Snape; Rinn Song; Richard Tarrant; Yrene Themistocleous; Kelly M Thomas; Tonya L Villafana; Sarah C Warren; Marion E E Watson; Alexander D Douglas; Adrian V S Hill; Teresa Lambe; Sarah C Gilbert; Saul N Faust; Andrew J Pollard
Journal:  Lancet       Date:  2020-11-19       Impact factor: 79.321

8.  Evaluation of Three Commercial SARS-CoV-2 Serologic Assays and Their Performance in Two-Test Algorithms.

Authors:  Sarah E Turbett; Melis Anahtar; Anand S Dighe; Wilfredo Garcia Beltran; Tyler Miller; Hannah Scott; Sienna Marie Durbin; Maheetha Bharadwaj; Jason Thomas; Tasos S Gogakos; Michael Astudillo; Jochen Lennerz; Eric S Rosenberg; John A Branda
Journal:  J Clin Microbiol       Date:  2020-12-17       Impact factor: 5.948
  8 in total
  108 in total

1.  One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19.

Authors:  Riccardo Levi; Elena Azzolini; Chiara Pozzi; Leonardo Ubaldi; Michele Lagioia; Alberto Mantovani; Maria Rescigno
Journal:  J Clin Invest       Date:  2021-06-15       Impact factor: 14.808

2.  Rapid decay of anti-SARS-CoV-2 antibodies in infection-naïve healthcare workers four months after vaccination.

Authors:  Maria Stamatopoulou; Vasileios Tsamadias; Theodosios Theodosopoulos; Stiliani Demeridou; George Kaparos; Nikolaos Memos; Manoussos Konstadoulakis; Stavroula Baka
Journal:  Germs       Date:  2021-12-29

3.  Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination.

Authors:  Rishi R Goel; Sokratis A Apostolidis; Mark M Painter; Divij Mathew; Ajinkya Pattekar; Oliva Kuthuru; Sigrid Gouma; Philip Hicks; Wenzhao Meng; Aaron M Rosenfeld; Sarah Dysinger; Kendall A Lundgreen; Leticia Kuri-Cervantes; Sharon Adamski; Amanda Hicks; Scott Korte; Derek A Oldridge; Amy E Baxter; Josephine R Giles; Madison E Weirick; Christopher M McAllister; Jeanette Dougherty; Sherea Long; Kurt D'Andrea; Jacob T Hamilton; Michael R Betts; Eline T Luning Prak; Paul Bates; Scott E Hensley; Allison R Greenplate; E John Wherry
Journal:  Sci Immunol       Date:  2021-04-15

4.  Is a single COVID-19 vaccine dose enough in convalescents ?

Authors:  Daniele Focosi; Andreina Baj; Fabrizio Maggi
Journal:  Hum Vaccin Immunother       Date:  2021-05-05       Impact factor: 3.452

5.  Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.

Authors:  Jonathan G Braun; Susan Cheng; Kimia Sobhani; Joseph E Ebinger; Justyna Fert-Bober; Ignat Printsev; Min Wu; Nancy Sun; John C Prostko; Edwin C Frias; James L Stewart; Jennifer E Van Eyk
Journal:  Nat Med       Date:  2021-04-01       Impact factor: 53.440

6.  Association between previous infection with SARS CoV-2 and the risk of self-reported symptoms after mRNA BNT162b2 vaccination: Data from 3,078 health care workers.

Authors:  Antonella d'Arminio Monforte; Alessandro Tavelli; Pier Mario Perrone; Alessandro Za; Katia Razzini; Daniele Tomasoni; Vittorio Bordoni; Luisa Romanò; Nicola Orfeo; Giulia Marchetti; Claudio Colosio
Journal:  EClinicalMedicine       Date:  2021-05-31

7.  Public trust on regulatory decisions: The European Medicines Agency and the AstraZeneca COVID-19 vaccine label.

Authors:  Rafael Dal-Ré; Odile Launay
Journal:  Vaccine       Date:  2021-06-04       Impact factor: 4.169

8.  Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination.

Authors:  Gian Luca Salvagno; Brandon M Henry; Giovanni di Piazza; Laura Pighi; Simone De Nitto; Damiano Bragantini; Gian Luca Gianfilippi; Giuseppe Lippi
Journal:  Diagnostics (Basel)       Date:  2021-05-04

9.  Tolerance of BNT162b2 mRNA COVI-19 vaccine in patients with a medical history of COVID-19 disease: A case control study.

Authors:  Aurelie Baldolli; Jocelyn Michon; Fanny Appia; Caroline Galimard; Renaud Verdon; Jean Jacques Parienti
Journal:  Vaccine       Date:  2021-06-23       Impact factor: 4.169

10.  Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of BNT162b2.

Authors:  Jean-Louis Bayart; Laure Morimont; Mélanie Closset; Grégoire Wieërs; Tatiana Roy; Vincent Gerin; Marc Elsen; Christine Eucher; Sandrine Van Eeckhoudt; Nathalie Ausselet; Clara David; François Mullier; Jean-Michel Dogné; Julien Favresse; Jonathan Douxfils
Journal:  Microorganisms       Date:  2021-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.